Evommune’s oral MRGPRX2 antagonist has failed to show benefit in patients with chronic spontaneous urticaria (CSU).
In a Phase IIb study (NCT06873516), EVO756 failed to meet its primary endpoint of mean change in a patient’s Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial enrolled 160 moderate-to-severe antihistamine-refractory CSU patients in the US, Europe, Canada and Japan. Patients received one of three active dose regimens or placebo.
Dr Eugene Bauer, CMO of Evommune, said: “EVO756 previously delivered positive Phase II data in chronic inducible urticaria and showed clear target engagement in the Phase I trial, however, the lack of efficacy demonstrated at week 12 in this Phase IIb trial does not support further development of EVO756 for CSU.”
EVO756 is being investigated in additional indications, including atopic dermatitis (AD) (NCT07150845) and migraine prophylaxis. While the drug will no longer be investigated in CSU, the other studies are set to continue, with data from the AD trial anticipated later in 2026.
EVO756 is a first-in-class, potent and highly selective oral small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on mast cells and peripheral sensory neurons.
Following the announcement, Evommune’s stock dropped 37.92%, to a low of $15.63 on 29 June, from $25.18 at close on 26 June (correct at 9.35am ET).
AD candidate showing promise
The company’s pipeline also includes EVO301, an IL-18BP fusion protein, which showed benefit in a Phase IIa trial in AD. After Evommune announced the data in February 2026, the company’s stock rose 70.86%, from a 9 February close of $16.99 to a 10 February close of $29.03.
According to GlobalData, parent company of Clinical Trials Arena, sales in the AD market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is estimated to grow from $8.5bn in 2023 to $22.4bn by 2033.
The AD market has grown significantly since Dupixent’s approval in 2017, a drug that now accounts for much of global drug sales in the disease. Sanofi has released data from its Dupixent successor, amlitelimab, with the trial meeting its primary endpoint. Sanofi is also speaking with regulators about the potential approval pathway for amlitelimab based on the Phase III trial data.
Filippos Maniatis, healthcare analyst at GlobalData, said: “AD is a growing market with an impressive pipeline of new products from current and future players in the field. The AD space was previously dominated by broad-acting immunomodulatory agents, which are now being slowly replaced by more targeted agents. This shift is likely due to better comprehension of the pathophysiology behind AD and the approval of several new systemic agents.”
